Should I buy or sell Health Catalyst stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCAT shares. View HCAT analyst ratings or view top-rated stocks .

What is Health Catalyst's stock price target for 2024?

10 brokers have issued 1-year price targets for Health Catalyst's shares. Their HCAT share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.40 in the next year. This suggests a possible upside of 79.9% from the stock's current price. View analysts price targets for HCAT or view top-rated stocks among Wall Street analysts .

How have HCAT shares performed in 2023?

Health Catalyst's stock was trading at $10.63 at the beginning of the year. Since then, HCAT shares have decreased by 29.9% and is now trading at $7.45. View the best growth stocks for 2023 here .

Are investors shorting Health Catalyst?

Health Catalyst saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,720,000 shares, an increase of 13.9% from the October 31st total of 1,510,000 shares. Based on an average trading volume of 466,800 shares, the days-to-cover ratio is presently 3.7 days. View Health Catalyst's Short Interest .

When is Health Catalyst's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our HCAT earnings forecast .

How were Health Catalyst's earnings last quarter?

Health Catalyst, Inc. (NASDAQ:HCAT) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The business had revenue of $73.77 million for the quarter, compared to analysts' expectations of $72.73 million. Health Catalyst had a negative net margin of 42.62% and a negative trailing twelve-month return on equity of 14.08%.

What ETFs hold Health Catalyst's stock?

ETFs with the largest weight of Health Catalyst (NASDAQ:HCAT) stock in their portfolio include Fidelity Digital Health ETF (FDHT) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) , SPDR FactSet Innovative Technology ETF (XITK) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) . iShares U.S. Healthcare Providers ETF (IHF) .

What guidance has Health Catalyst issued on next quarter's earnings?

Health Catalyst issued an update on its third quarter 2023 earnings guidance on Friday, October, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $73.77 million-$73.77 million, compared to the consensus revenue estimate of $72.66 million.

What is Dan Burton's approval rating as Health Catalyst's CEO?

501 employees have rated Health Catalyst Chief Executive Officer Dan Burton on Glassdoor.com . Dan Burton has an approval rating of 99% among the company's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Health Catalyst to a friend.

What other stocks do shareholders of Health Catalyst own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA) , Salesforce (CRM) , Alteryx (AYX) , Walt Disney (DIS) , DocuSign (DOCU) , Block (SQ) , Slack Technologies (WORK) , ServiceNow (NOW) , Marvell Technology (MRVL) and PayPal (PYPL) .

When did Health Catalyst IPO?

(HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

Who are Health Catalyst's major shareholders?

Health Catalyst's stock is owned by a number of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (3.44%), Primecap Management Co. CA (1.95%), Nepsis Inc. (1.59%), Bank of New York Mellon Corp (1.50%), Jacobs Levy Equity Management Inc. (1.33%) and Bares Capital Management Inc. (1.22%). Insiders that own company stock include Anita Pramoda , Benjamin Landry, Bryan Richard Hinton , Bryan Truman Hunt , Daniel D Burton , Daniel H Orenstein , Duncan Gallagher, James Patrick Jr Nelli , Jason Alger , Linda Llewelyn , Paul Horstmeier and Timothy G Ferris. View institutional ownership trends .

How do I buy shares of Health Catalyst?

Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Health Catalyst (HCAT) Stock Price, News & Analysis

$7.40

-0.36 (-4.64%)

(As of 11:04 AM ET)

Compare

Today's Range: $7.35
▼
$7.66
50-Day Range: $6.71
▼
$10.16
52-Week Range: $6.60
▼
$15.87

Volume: 104,481 shs
Average Volume: 479,310 shs
Market Capitalization: $425.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.40

Health Catalyst MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 79.9% Upside
$13.40 Price Target
Short Interest: Healthy
2.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.91
Upright™ Environmental Score
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: Selling Shares
$38,879 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.90) to ($0.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

283rd out of 942 stocks

Health Information Services Industry

3rd out of 7 stocks

3.3

Analyst's Opinion

Consensus Rating
Health Catalyst has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.40, Health Catalyst has a forecasted upside of 79.9% from its current price of $7.45.
Amount of Analyst Coverage
Health Catalyst has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.99% of the outstanding shares of Health Catalyst have been sold short.
Short Interest Ratio / Days to Cover
Health Catalyst has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Health Catalyst has recently increased by 13.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Health Catalyst does not currently pay a dividend.
Dividend Growth
Health Catalyst does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Health Catalyst has received a 48.83% net impact score from Upright. Health Catalyst seems to create the most significant positive value in categories "Taxes", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is mostly driven by its "Health data collection software", "Data analytics services", and "Drug discovery software" products. See details.
Environmental Sustainability
The Environmental Impact score for Health Catalyst is -0.91.

2.2

News and Social Media Coverage

News Sentiment
Health Catalyst has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Health Catalyst this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for HCAT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
3 people have added Health Catalyst to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Health Catalyst insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,879.00 in company stock.
Percentage Held by Insiders
Only 2.70% of the stock of Health Catalyst is held by insiders.
Percentage Held by Institutions
86.63% of the stock of Health Catalyst is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Health Catalyst are expected to grow in the coming year, from ($0.90) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Health Catalyst is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Health Catalyst is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Health Catalyst has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Health Catalyst Stock (NASDAQ:HCAT)

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases. It also provides services expertise, which include data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.

HCAT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HCAT Stock News Headlines

December 11, 2023 | americanbankingnews.com

Critical Review: Health Catalyst (NASDAQ:HCAT) and Taboola.com (NASDAQ:TBLA)

December 6, 2023 | bizjournals.com

Portland health care AI startup names new CEO

December 11, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 2, 2023 | americanbankingnews.com

Financial Comparison: Health Catalyst (NASDAQ:HCAT) and Taboola.com (NASDAQ:TBLA)

November 13, 2023 | msn.com

Piper Sandler Upgrades Health Catalyst (HCAT)

November 13, 2023 | finance.yahoo.com

Health Catalyst (HCAT) Stock Trades Up, Here Is Why

November 7, 2023 | finance.yahoo.com

Health Catalyst, Inc. (NASDAQ:HCAT) Q3 2023 Earnings Call Transcript

November 6, 2023 | finance.yahoo.com

Health Catalyst Inc (HCAT) Reports 8% Revenue Growth in Q3 2023

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 2, 2023 | finance.yahoo.com

Compared to Estimates, Health Catalyst (HCAT) Q3 Earnings: A Look at Key Metrics

November 2, 2023 | finance.yahoo.com

Health Catalyst Acquires ERS, Bolsters Tech-Enabled Managed Services Offering with Data Abstraction and Oncology Registry Management Capabilities

November 2, 2023 | finance.yahoo.com

Accountable Health Partners, A Clinically Integrated Network, Signs Multi-Year Partnership with Health Catalyst to Advance Operational Improvements

November 2, 2023 | finance.yahoo.com

Health Catalyst Reports Third Quarter 2023 Results

November 2, 2023 | axios.com

General Catalyst hospital play flips VC script, finds new hurdles

October 31, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Generation Bio (GBIO), Health Catalyst (HCAT)

October 30, 2023 | axios.com

General Catalyst enters a "struggle for the soul" of the US hospital

October 27, 2023 | msn.com

Health Catalyst raises FY revenue outlook

October 27, 2023 | finance.yahoo.com

Health Catalyst Reports Third Quarter 2023 Preliminary Results

October 26, 2023 | axios.com

General Catalyst hospital: A risky bet with worthy ambitions

October 25, 2023 | finance.yahoo.com

Health Catalyst to Announce Third Quarter 2023 Operating Results and Host Conference Call on Wednesday, November 8, 2023

October 22, 2023 | finance.yahoo.com

Health Catalyst Insider Ups Holding By 42% During Year

October 17, 2023 | finance.yahoo.com

All You Need to Know About Health Catalyst (HCAT) Rating Upgrade to Strong Buy

October 14, 2023 | msn.com

Wall Street Breakfast Catalyst Watch: Weight Loss Drugs Make An Impact

October 14, 2023 | techcrunch.com

Deal Dive: Why does General Catalyst want to buy a healthcare system?

September 27, 2023 | finance.yahoo.com

Health Catalyst Pop Analyzer™ and Health Catalyst Care Flow™ Achieve NCQA Population Health Management Prevalidation Status

September 15, 2023 | nasdaq.com

Cantor Fitzgerald Reiterates Health Catalyst (HCAT) Overweight Recommendation

September 5, 2023 | finance.yahoo.com

Health Catalyst Recognized in Five Gartner® Hype Cycle™ Reports

See More Headlines

Receive HCAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Health Catalyst and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Information Services
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HCAT
CUSIP: N/A
CIK: 1636422
Web: www.healthcatalyst.com
Phone: (801) 708-6800
Fax: N/A
Employees: 1,200
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.40
High Stock Price Target: $18.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +72.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-137,400,000.00
Net Margins: -42.62%
Pretax Margin: -42.53%
Return on Equity: -14.08%
Return on Assets: -7.67%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 4.85
Quick Ratio: 4.85

Sales & Book Value

Annual Sales: $276.24 million
Price / Sales: 1.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.76 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 57,550,000
Free Float: 55,996,000
Market Cap: $446.59 million
Optionable: Not Optionable
Beta: 1.29

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Daniel D. Burton (Age 48)
CEO & Director
Comp: $158.9k
Mr. Bryan Truman Hunt (Age 36)
Chief Financial Officer
Comp: $370.46k
Mr. Daniel H. Orenstein (Age 53)
Senior Advisor
Comp: $356.56k
Mr. Kevin Freeman (Age 50)
Chief Commercial Officer
Comp: $405.9k
Ms. Anne Marie Bickmore (Age 60)
COO & Chief Product Officer
Mr. Jason Alger (Age 39)
Chief Accounting Officer
Mr. Dave Ross
Chief Technology Officer
Mr. Adam Brown
Senior Vice President of Investor Relations and Financial Planning & Analysis
Mr. Benjamin Landry
General Counsel & Secretary of the Board
Ms. Tarah Neujahr Bryan
Chief Marketing & Communications Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HCAT Stock Analysis - Frequently Asked Questions

Should I buy or sell Health Catalyst stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCAT shares.
View HCAT analyst ratings or view top-rated stocks.
What is Health Catalyst's stock price target for 2024?: 10 brokers have issued 1-year price targets for Health Catalyst's shares. Their HCAT share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.40 in the next year. This suggests a possible upside of 79.9% from the stock's current price.
View analysts price targets for HCAT or view top-rated stocks among Wall Street analysts.
How have HCAT shares performed in 2023?: Health Catalyst's stock was trading at $10.63 at the beginning of the year. Since then, HCAT shares have decreased by 29.9% and is now trading at $7.45.
View the best growth stocks for 2023 here.
Are investors shorting Health Catalyst?: Health Catalyst saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,720,000 shares, an increase of 13.9% from the October 31st total of 1,510,000 shares. Based on an average trading volume of 466,800 shares, the days-to-cover ratio is presently 3.7 days.
View Health Catalyst's Short Interest.
When is Health Catalyst's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our HCAT earnings forecast.
How were Health Catalyst's earnings last quarter?: Health Catalyst, Inc. (NASDAQ:HCAT) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The business had revenue of $73.77 million for the quarter, compared to analysts' expectations of $72.73 million. Health Catalyst had a negative net margin of 42.62% and a negative trailing twelve-month return on equity of 14.08%.
What ETFs hold Health Catalyst's stock?: ETFs with the largest weight of Health Catalyst (NASDAQ:HCAT) stock in their portfolio include Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR FactSet Innovative Technology ETF (XITK) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).

What guidance has Health Catalyst issued on next quarter's earnings?: Health Catalyst issued an update on its third quarter 2023 earnings guidance on Friday, October, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $73.77 million-$73.77 million, compared to the consensus revenue estimate of $72.66 million.
What is Dan Burton's approval rating as Health Catalyst's CEO?: 501 employees have rated Health Catalyst Chief Executive Officer Dan Burton on Glassdoor.com. Dan Burton has an approval rating of 99% among the company's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Health Catalyst to a friend.
What other stocks do shareholders of Health Catalyst own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA), Salesforce (CRM), Alteryx (AYX), Walt Disney (DIS), DocuSign (DOCU), Block (SQ), Slack Technologies (WORK), ServiceNow (NOW), Marvell Technology (MRVL) and PayPal (PYPL).
When did Health Catalyst IPO?: (HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.
Who are Health Catalyst's major shareholders?: Health Catalyst's stock is owned by a number of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (3.44%), Primecap Management Co. CA (1.95%), Nepsis Inc. (1.59%), Bank of New York Mellon Corp (1.50%), Jacobs Levy Equity Management Inc. (1.33%) and Bares Capital Management Inc. (1.22%). Insiders that own company stock include Anita Pramoda, Benjamin Landry, Bryan Richard Hinton, Bryan Truman Hunt, Daniel D Burton, Daniel H Orenstein, Duncan Gallagher, James Patrick Jr Nelli, Jason Alger, Linda Llewelyn, Paul Horstmeier and Timothy G Ferris.
View institutional ownership trends.
How do I buy shares of Health Catalyst?: Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HCAT) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Health Catalyst (HCAT) Stock Price, News & Analysis

Health Catalyst MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Health Catalyst Stock (NASDAQ:HCAT)

HCAT Stock Price History

HCAT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

HCAT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™